Screener
Aurinia Pharmaceuticals AUPH Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Aurinia Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:16 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001600620-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Net income | $71,769 | $44,857 |
| Adjustments to reconcile net income to cash flows from operating activities: | ||
| Deferred income tax | 20,387 | — |
| Share-based compensation | 1,973 | 2,031 |
| Amortization and depreciation | 9,650 | 9,720 |
| Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | (977) | 9,265 |
| Net amortization of premiums and discounts on investments | (4,200) | (5,219) |
| Other, net | (2,082) | 4,132 |
Item 1. Financial Statements.
FAQ
- What is Aurinia Pharmaceuticals's stock-based comp?
- Aurinia Pharmaceuticals (AUPH) reported stock-based comp of $2.84M in Q2 2026.
- How has Aurinia Pharmaceuticals's stock-based comp changed year-over-year?
- Aurinia Pharmaceuticals's stock-based comp decreased by 47.8% year-over-year, from $5.44M to $2.84M.
- What is the long-term trend for Aurinia Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's stock-based comp has grown at a -17.2% compound annual growth rate (CAGR), from $31.24M to $14.68M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Aurinia Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude